SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-24-115850
Filing Date
2024-04-26
Accepted
2024-04-26 07:56:57
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d804556ddefa14a.htm DEFA14A 12022
2 GRAPHIC g804556g02g02.jpg GRAPHIC 426295
3 GRAPHIC g804556g03g03.jpg GRAPHIC 167799
  Complete submission text file 0001193125-24-115850.txt   831456
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40489 | Film No.: 24878843
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)